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ABSTRACT
In this study, we generated transgenic (Tg) mice, which overexpressed 
transforming growth factor (TGF)-β stimulated clone-22 (TSC-22), and investigate the 
functional role of TSC-22 on their development and pathogenesis. We obtained 13 Tg-
founders (two mice from C57BL6/J and 11 mice from BDF1). Three of 13 Tg-founders 
were sterile, and the remaining Tg-founders also could generate only a limited number 
of the F1 generation. We obtained 32 Tg-F1 mice. Most of the Tg-mice showed marked 
obesity. Histopathological examination could be performed on 31 Tg-mice; seventeen 
mice died by some disease in their entire life and 14 mice were killed for examination. 
Most of the Tg-mice examined showed splenic abnormality, in which marked increase 
of the megakaryocytes, unclearness of the margin of the red pulp and the white pulp, 
and the enlargement of the white pulp was observed. B cell lymphoma was developed 
in 10 (71%) of 14 disease-died F1 mice. These results indicate that constitutive over-
expression of TSC-22 might disturb the normal embryogenesis and the normal lipid 
metabolism, and induce the oncogenic differentiation of hematopoietic cells.
INTRODUCTION
Transforming growth factor (TGF)-β stimulated 
clone-22 (TSC-22) was originally isolated as a TGF-
β-inducible gene in mice osteoblastic cells, MC3T3E1 
[1]. Then, TSC-22 was shown to encode a putative 
transcriptional regulator containing a leucine zipper-like 
structure [1]. Subsequently, TSC-22 was demonstrated to 
be up-regulated by many different stimuli such as TPA, 
choleratoxin, dexamethasone [1], follicle-stimulating 
hormone [2], tumor necrosis factor α, interferon-γ, 
interleukin-1β, lipopolysaccharide [3], progesterone [4], 
and epidermal growth factor (EGF) [5]. We identified 
human TSC-22 as an anti-cancer drug (Vesnarinone)-
inducible gene in a human salivary gland cancer cell line, 
TYS [6, 7]. Recently we [8] and other investigators [9] 
demonstrated that upregulation of TSC-22 mediated by 
TGF-β can be a post-transcriptional regulation via some 
microRNAs. TSC-22 contained leucine zipper motif 
and TSC-box but did not have a classical DNA-binding 
domain as bZip or bHLH-Zip families did. Therefore, 
TSC-22 was hypothesized to act as a transcritptional 
regulator by binding other leucine zipper containing 
transcription factors. Ohta et al. reported TSC-22 as a 
transcription factor for C-type natriuretic peptide gene 
[3]. However, we and Kester et al. recently reported 
that TSC-22 acted as a transcriptional enhancer [10] or 
repressor [11] when fused to the DNA binding domain 
of yeast transcription factor GAL4. Thus, the mechanism 
underlying the transcriptional up-regulation of TSC-22 
remained obscure.
Concerning the role of TSC-22 on cell growth 
and differentiation, and tumorigenesis, we reported that 
TSC-22 negatively regulated the growth of TYS cells [6], 
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and that downregulation of TSC-22 in TYS cells played 
a major role in the salivary gland tumorigenesis [7]. 
Subsequently, we reported that overexpression of TSC-22 
enhanced chemosensitivity and radiation-sensitivity by 
inducing apoptosis in the cancer cells [12-14]. Recently, 
Yu et al. and Kato et al. reported the characteristics of the 
TSC-22 deficient mice [9, 15]. They concluded that TSC-
22 had a tumor suppressor function in T or natural killer 
large granular lymphocyte leukemia, and carcinogen–
induced liver tumor.
On the other hand, several investigators clarified 
the crucial role of TSC-22 on the development of 
Drosophila and mice [16-20]. Treisman et al. [16], Kania 
et al. [17] and Dobens et al. [18] found that Drosophila 
TSC-22 gene, shortsighted or bunched, was essential 
for the Drosophila development, and that Drosophila 
TSC-22 gene was an effector gene which could integrate 
multiple extracellular signals. Furthermore, Dohrmann 
et al. [19] and Kester et al. [20] demonstrated that, 
during mouse embryogenesis, TSC-22 was upregulated 
at sites of epithelial-mesenchymal interaction and 
expressed in many neural crest-derived tissues.
In this study, we generated transgenic mice, which 
overexpressed TSC-22 in most of the cells in the entire 
body, and investigated the functional role of TSC-22 on 
the development and pathogenesis of mice.
RESULTS
Expression of EGFP-TSC-22 fusion proteins in 
TYS cells from the transgenic cassette
We transiently transfected TYS cells with the 
transgenic cassette containing EGFP-TSC-22 fusion gene 
(Figure 1A). GFP fluorescence was observed only in 
the cytoplasm but not in the nucleus in the EGFP-TSC-
22-transfectants (data not shown). As we have already 
reported [10, 13], TSC-22 protein contains a nuclear 
export signal (NES), and localizes to cytoplasm in the 
live cells. By Western blotting (Figure 1B), we confirmed 
the expression of EGFP-TSC-22 fusion protein (45 kDa) 
in the EGFP-TSC-22 transfectants, but not in the control 
transfectants (pEGFP-C3).
Generation of TSC-22 transgenic mice 
expressing EGFP-TSC-22 fusion protein
We transferred 134 DNA-injected embryos to 
C57BL6/J pseudopregnant foster mothers; however, we 
obtained only 21 mice (Table 1). Moreover, only 2 mice 
(one male and one female) were positive for TSC-22 
transgene in the 21 born mice (Table 1). The ratio of the 
born mice per transferred embryos (15.7%) and the ratio 
of the transgene-positive mice per born mice (9.5%) were 
much lower than the ratio in other gene transferred mice in 
this institute. Then, we changed the mouse strain from in-
bred (C57BL6/J) to hybrid (BDF1). We transferred more 
than 300 DNA-injected embryos to BDF1 pseudopregnant 
foster mothers, and obtained 121 mice. Eleven mice (seven 
male and four female) were positive for TSC-22 transgene 
in the 121 born mice (9.0%).
Genotyping of the transgenic mice were performed 
by the PCR amplification of the EGFP-TSC-22 gene. 
Transgene-positive mice produced 490 bp band by 
the PCR amplification as shown in Figure 2A. The 
expression of mRNA from the EGFP-TSC-22 gene in 
the transgene-positive mice was examined by RT-PCR 
as described above. Transgene-positive mice certainly 
expressed EGFP-TSC-22 mRNA at very high level (data 
not shown). Furthermore, the expression of the EGFP-
TSC-22 fusion protein was confirmed in the cultured 
keratinocytes obtained from the transgene-positive mice. 
GFP fluorescence (EGFP-TSC-22 fusion protein) was 
clearly observed in the cytoplasm but not in the nucleus 
in the keratinocytes (Figure 2B).
Breeding of transgenic mice
Number of the transgene-positive F1 mice in 
each TSC-22 transgenic founder was shown in Table 2. 
Female transgenic founder in C57BL/6 strain bore total 
22 pups at four times delivery; however, none of the 
pups were transgene positive. Moreover, male transgenic 
founder in C57BL/6 strain was sterile. Transgenic 
founders in BDF1 strain produced several F1 transgene-
positive mice. Number of the pups at one delivery was 
extremely limited at the range from 0 to 11 (average 6) 
both in male and female BDF1 transgenic founder. One 
male and one female BDF1 transgenic founders were 
sterile. Furthermore, the ratio of the transgene-positive 
F1 mice per born mice was extremely low. We obtained 
32 transgene-positive F1 mice, 12 male and 20 female.
Overexpression of TSC-22 causes marked 
obesity in mice
Most of the TSC-22 transgenic mice showed 
marked obesity. As shown in Figure 3AB, body weight 
of the transgenic mice was much higher than that of wild 
type C57BL6 or BDF1 (data was obtained from Clea 
Japan web site; http://www.clea-japan.com/animalpege/
a_1/e_02.html or http://www.clea-japan.com/animalpege/
a_1/f_02.html). Especially, the body weight of the P♀5 
(BDF1) was over 60 g, which was twice as that of wild 
type. The accumulation of the subcutaneous fat tissue and 
the intra-abdominal fat tissue was observed (Figure 3C). 
Most of the F1 mice inherited the phenotype, obesity from 
the founder.
Histopathological abnormality and a principal 
cause of death of TSC-22 transgenic mice
Nine of 13 founder TSC-22 transgenic mice 
(Table 3) and 22 of 32 F1 TSC-22 transgenic mice were 
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available for histopathological examination (Table 4). 
In 31 transgenic mice examined, 17 mice died by some 
disease in their entire life and 14 mice were killed 
for examination. Most of the transgenic mice showed 
splenic abnormality, in which marked increase of the 
megakaryocytes, unclearness of the margin of the red pulp 
and the white pulp, and the enlargement of the white pulp 
was observed (Figure 4A, 4B). Lymphoma (Figure 4C) 
was developed in ten (71%) of 14 F1 mice died by some 
disease. Hemangioma in the liver or spleen was observed 
in five (29%) of the 17 mice. Most of the transgenic mice 
with obesity showed the marked fatty-degeneration of 
hepatocytes (Figure 4D). Pulmonary emphysema was 
developed in 4 of the 17 mice, and adenocarcinoma 
of the lung was observed in 3 of the 14 F1 mice. 
Immunohistochemistry by a monoclonal antibody HM57 
clearly showed the expression of CD79α on the lymphoma 
cells (Figure 4E), then all of the lymphoma was confirmed 
to be B cell lymphoma.
Figure 1: Structure and expression of the EGFP-TSC-22 fusion gene. A. Schematic structure of the TSC-22 transgenic cassette. 
Transgenic cassette contains human TSC-22 fragment fused to EGFP under the transcriptional control of CAG promoter. The human 
TSC-22-EGFP fusion gene was followed by the first intron of Protamine gene containing the poly-adenylation signal. B. Expression of 
EGFP-TSC-22 fusion proteins from the transgenic cassette in a human salivary gland cell line, TYS cells. TYS cells were transfected with 
the transgenic cassette. Forty-eight hours after transfection, cell lysates were prepared from the transfectants, and the expression of EGFP-
TSC-22 fusion protein (45 kDa) was examined by Western blotting.
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Blood analysis of the TSC-22 transgenic mice
The average and standard deviation of the number 
of red blood cells, white blood cells, and platelets in the 
blood of 20 transgenic mice were 713 ± 121 ×104/μl, 6226 
± 2951/μl, 90 ± 44 ×104/μl, respectively. The average 
and standard deviation of serum glucose levels in 22 
transgenic mice was 161 ± 38 mg/dl. These data in the 
transgenic mice were almost the same as that of wild type 
BDF1 (data was obtained from Clea Japan web site; http://
www.clea-japan.com/animalpege/a_1/f_03.html).
DISCUSSION
Several investigators have demonstrated that TSC-
22 regulates cell growth and differentiation as well as cell 
death [1-4, 6, 7, 21], and that TSC-22 is required for the 
embryonic development [16-20]. Expression of TSC-22 
mRNA was reported to be detectable at 6.5 day embryos 
ubiquitously [19]. TSC-22 was upregulated at the site of 
epithelial-mesenchymal interaction, such as limb bud, 
tooth germ, hair follicle, kidney, lung, and pancreas. 
TSC-22 was also upregulated at neural crest derived 
tissues, heart, otic and optic vesicle, and cartilage and 
bone forming region throughout the embryo [19, 20]. In 
the present study, number of the pups at one delivery was 
extremely limited, and the ratio of the transgene-positive 
F1 mice per born mice was extremely low. Although these 
reasons remain unclear, artificial over-expression of TSC-
22 during embryogenesis might inhibit several epithelial-
mesenchymal interactions and disturb normal development 
of the embryos in the transgenic mouse. More detail 
histopathological examinations concerning embryogenesis 
in this transgenic mouse must be conducted.
Jay et al. reported the expression of TSC-22 in 
adult mouse [22]. TSC-22 mRNA was highly expressed 
at ovary, small intestine, colon, heart, and brain, and 
moderately expressed at thymus, prostate, testis, placenta, 
skeletal muscle, and pancreas, and faintly expressed at 
spleen, lung, liver, and kidney in adult mouse. However, 
TSC-22 was not expressed in leukocytes in adult mouse. 
Interestingly, abnormal organs in our transgenic mouse 
were almost corresponding to the organs with limited 
TSC-22 expression in adult mouse. Constitutive over-
expression of the TSC-22 in the organs with limited TSC-
22 expression in adult mouse might inhibit the growth of 
the cells and/or cause the differentiation abnormality of 
the cells. Yu et al. [15] and Nakamura et al. [23] generated 
the TSC-22 knock-out mice, and they showed its crucial 
role on the proliferation and the repopulation efficacy of 
hematopoietic precursor cells, and on the oncogenic Ras/
Raf signaling, respectively. However, Yu et al. described 
that TSC-22 knock-out mice showed slight weight 
decrease of kidneys and hearts, and Nakamura et al. 
mentioned that TSC-22 knock-out mice were born at 
the expected Mendelian ratio and showed no obvious 
abnormality. In the TSC-22 knock-out mice, other TSC-
22 families might compensate the role TSC-22 on the 
development of the mouse.
Some investigators reported the implication of TSC-
22 on type 2 Diabetes or lipid metabolism [9, 24-26]. In 
our transgenic mice, blood glucose level was not elevated, 
and renal fibrosis was not observed. At present, we could 
not clearly explain why our transgenic mice became fat, 
we should examine the food and water intake, eliminative 
behavior, and motor behavior in the metabolic gage.
From the beginning of the discovery of TSC-22 [1, 
2, 6, 7], TSC-22 was considered as a tumor suppressor, 
a differentiation induce, or a negative growth regulator. 
Further consolidation data was continuously published 
in several journals [27-34]. However, in our transgenic 
mice, frequent development of B cell lymphoma 
was observed. Although Yamate et al. reported that 
malignant lymphoma was developed in wild type 
BDF1 mice allowed to live out their life-span [35], in 
our experiment, B cell lymphoma was developed in 
59% of the disease-died transgenic mice. Most of the 
Tg-mice examined showed splenic abnormality, such 
as unclearness of the margin of the red pulp and the 
white pulp, and the enlargement of the white pulp. 
These observations suggested that several abnormalities 
might occur in the lymphocytes of the transgenic 
mice after survival of the growth suppression, the 
induction of apoptosis and the differentiation during 
the embryogenesis and the development. Therefore, 
lymphocytes in the born-TSC-22 transgenic mice might 
be susceptible for the development of lymphoma. TSC-
22 was previously reported to inhibit the development 
of several hematopoietic malignancies [15, 31], and 
enhance the differentiation of the several hematopoietic 
cells [36]. Therefore, our transgenic mouse might be 
useful for examining the pathogenesis of hematopoietic 
malignancy as well as the metabolic abnormality and 
obesity.
Table 1: Number of transgene-positive mice
No. of transferred
DNA-injected 
embryos
No. of Tg-positive 
mice
/No. of born mice
(% Tg-positive mice)
C57BL6/J 134 2 (♂: 1, ♀: 1)/21 9.5%
BDF1 >300 11 (♂: 7, ♀: 4)/121 9.0%
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MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors' 
institutional review board.
Construction of the transgenic cassette
Transgenic cassette (Figure 1A) was constructed 
as follows: pCAGPrm was digested with EcoRV (Takara 
Biomedicals, Kusatsu, Japan) and BamH1 (Takara 
Biomedicals). The human TSC-22 cDNA fragment fused 
to enhanced green fluorescent protein (EGFP) cDNA 
was excised from pEGFP-TSC-22FL [10] by digesting 
with Eco47III (Takara Biomedicals) and BamH1 (Takara 
Biomedicals). Then, the human TSC-22 fragment fused 
to EGFP was ligated to the prepared cloning site of 
pCAGPrm, and pCAGPrm-TSC-22FL was generated. 
The direction of the ligated fragment from the promoter 
and the sequence of the ligated site in the plasmid 
were confirmed by sequencing analysis (Amersham 
Pharmacia Biotech., Uppsala, Sweden; Shimadzu 
DSQ-500 DNA sequencer, Shimadzu, Kyoto, Japan). 
Figure 2: Generation of EGFP-TSC-22 transgenic mice. A. Genotyping of transgenic mice. Genotyping of transgenic mice were 
performed by the PCR amplification of the EGFP-TSC-22 gene. Genomic DNA was extracted from ear biopsies. The 490 bp of human EGFP-
TSC-22 fusion gene in the transgenic cassette was amplified. B. Expression of EGFP-TSC-22 fusion protein in the transgenic founders. The 
expression of the EGFP-TSC-22 fusion protein was confirmed in the cultured keratinocytes obtained from the transgene-positive mice. GFP 
fluorescence (EGFP-TSC-22 fusion protein) was clearly observed in the cytoplasm but not in the nucleus in the keratinocytes.
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pCAGPrm-TSC-22FL contained human TSC-22 fragment 
fused to EGFP under the transcriptional control of CAG 
promoter, which was composed of chicken actin promoter 
and cytomegalovirus immediate early promoter (CMV-
IE). It is well known that the CAG promoter is one of the 
strongest promoters in the wide variety of the mammalian 
cells, and induces constitutive expression of the regulating 
gene [37]. The human TSC-22 fragment fused to EGFP 
was followed by the first intron of Protamine gene 
containing the poly-adenylation signal. Then, transgenic 
cassette (Figure 1A) was excised from pCAGPrm-TSC-
22FL by digesting with Ase1 (Takara Biomedicals) and 
Spe1 (Takara Biomedicals).
Determination of the expression of EGFP-
TSC-22 fusion proteins from the transgenic 
cassette in TYS cells
A human salivary gland cell line, TYS cells [38] 
(5 x 105 cells/dish) were seeded in 60-mm culture dishes 
(Falcon; Becton Dickinson Labware, Lincoln Park, 
NJ) in DMEM (Life Technologies, Inc., Gaithersburg, 
MD) supplemented with 10% FCS (Bio-Whittaker, 
Walkersville, MD), 100 μg/ml streptomycin, 100 U/
ml penicillin (Life Technologies, Inc.), and 0.25 μg/ml 
amphotericin B (Life Technologies, Inc.) in a humidified 
atmosphere of 95% air and 5% CO
2
 at 37°C. Twenty-four 
h later, the cells were transfected with 1 μg of transgenic 
cassette using Superfect regent (QIAGEN, Hilden, 
Germany).
The expression of EGFP-TSC-22 fusion protein 
from the transgenic cassette was first examined in 
cultured-TYS cells by observing the GFP fluorescence. 
Forty-eight hours after transfection, GFP fluorescence 
was observed by a fluorescent-microscopy excited by 
495 nm blue light on the transfectants (Nikon, Tokyo, 
Japan). Subsequently, expression of the fusion protein 
was confirmed by Western blotting using an anti-
TSC-22 antibody [7]. Cell lysates were prepared from 
the transfectants by use of the cell lysis buffer [50 mM 
HEPES (pH 7.5) containing 150 mM NaCl, 1% Triton 
X-100, 1.5 mM MgCl
2
, 1 mM EDTA, 10 mM sodium 
pyrophosphate, 100 mM sodium orthovanadate, 100 mM 
NaF, 100 mM p-nitrophenyl phosphate, 5 U/ml aprotinin, 
and 1 mM phenylmethylsulfonyl fluoride]. The protein 
concentrations of the samples were determined by Bio-
Rad protein assay (Bio-Rad, Hercules, CA). One hundred 
microgram of protein samples were electrophoresed 
on SDS-polyacrylamide gel. Proteins from gels were 
transferred to nitrocellulose (Bio-Rad), and the membrane 
was incubated with the affinity purified anti-TSC-22 
antibody, and an Amersham ECL kit (Amersham 
Pharmacia Biotech.).
Generation of TSC-22 transgenic mice
The transgenic founders were generated at 
Laboratory Animal Resource Center, University of Tsukuba 
under the control of Animal Care and Use Committee, 
University of Tsukuba. The transgenic cassette was injected 
into pronucleus of one cell-stage of embryos obtained from 
C57BL6/J (Clea Japan, Tokyo, Japan) or BDF1 (Clea 
Japan). The embryos were transferred to pseudopregnant 
foster mothers. After obtaining pups, the TSC-22 transgenic 
Table 2: Number of transgene-positive F1 mice in each TSC-22 transgenic founder mice
Founders 1st delivery 2nd delivery 3rd delivery 4th delivery 5th 
delivery
P♀1 (C57BL/6) 0/6a (♂3, ♀3) 0/9 (♂4, ♀5) 0/7 (♂5, ♀2)
P♀2 (BDF1) 0/4 (♂2, ♀2) 0/2 (♂2, ♀0) 2 (♂1, ♀1)/4 (♂1, ♀3) 1 (♀1)/2
P♀3 (BDF1) sterile
P♀4 (BDF1) 0/1 (♂1) 0/7 (♂3, ♀4) 0/7 3 (♂2, ♀1)/7
P♀5 (BDF1) 3 (♀3)/10 (♂3, ♀7) 2 (♂1, ♀1)/9 (♂5, ♀4) 0/2 0/7 (♂1, ♀2)
P♂1 (C57BL/6) sterile
P♂2 (BDF1) sterile
P♂3 (BDF1) 0/7 (♂4, ♀3) 1 (♀1)/11 (♂6, ♀5) 2 (♂1, ♀1)/9
P♂4 (BDF1) 0/4 (♂2, ♀8) 1 (♂1)/7 0/7 (♂5, ♀2) 3 (♀3)/7
P♂5 (BDF1) 0/1 (♂1) 0/8 (♂5, ♀3) 1 (♀1)/9
P♂6 (BDF1) 0/4 (♂2, ♀2) 0/4 (♂5, ♀3) 0/4 (♂1, ♀5) 0/6
P♂7 (BDF1) 2 (♀2)/8 (♂1, ♀7) 0/9 (♂?, ♀?) 4 (♂4)/10 5 (♀5)/10
P♂8 (BDF1) 0/1 (♂1) 0/5 (♂3, ♀2) 1 (♂1)/9 0/10 (♂1, ♀9) 1 (♂1)/9
aNumber of transgene-positive mice/number of born mice.
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Figure 3: Overexpression of TSC-22 causes marked obesity in mice. Most of the TSC-22 transgenic mice showed marked 
obesity both in female A. and male B. The accumulation of the subcutaneous fat tissue and the intra-abdominal fat tissue was observed. 
Body weight of the transgenic mice was much higher than that of wild type C57BL6 or DBA2. Horizontal bars in each graph show the 
mean weight of adult mice.
(Continued )
founders were distinguished by amplifying the human 
TSC-22-GFP fusion gene in the transgenic cassette using 
polymerase chain reaction (PCR) method. Genomic DNA 
was extracted from ear biopsies. The ear biopsies were 
incubated in 200 μl of the extracting buffer [10 mM Tris-
HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl2, 0.1 mg/ml 
Gelatin, 0.45% Nonidet P-40, 0.45% Tween 20, 0.2 mg/
ml Proteinase K] for 8 hours at 56 °C, and boiled for 
15 minutes. Then, the supernatants were obtained by 
centrifugation at 15,000 rpm for 10 minutes at 15°C. 
Subsequently, one microliter of the supernatants, which 
contained genomic DNA from the mice, was subjected to 
PCR amplification. The 490 bp of human TSC-22-GFP 
fusion gene in the transgenic cassette was amplified by a 
pair of primers (5’-CAA CAT CCT GGG GCA CAA GC-3’ 
as an up-stream primer, and 5’-CCA CAC TTG CAC CAG 
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Figure 3 (Continued): C. The body weight of the P♀5 (BDF1) was over 60 g, which was twice as that of wild type. Most of the F1 mice 
inherited the phenotype, obesity from the founder.
Figure 4: Histopathological abnormality of TSC-22 transgenic mice. A, B. Most of the transgenic mice showed splenic 
abnormality, in which marked increase of the megakaryocytes, unclearness of the margin of the red pulp and the white pulp, and the 
enlargement of the white pulp was observed. C. Malignant lymphoma was developed in ten (71%) of 14 disease-died F1 mice. Malignant 
lymphoma invaded into the kidney. D. Most of the transgenic mice with obesity showed the marked fatty-degeneration of hepatocytes. E. 
Immunohistochemistry by a monoclonal antibody HM57 clearly showed the expression of CD79α on the cell surface.
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Table 3: Possible cause of death and histopathological features of TSC-22 transgenic founder mice
Founder mice Died or killed Possible cause of 
death
Histopathological features
P♀1 (C57BL/6)
Died at 2 years 1 
month
Renal failure
Adenoma in lung, fibrosis of nephron, 
skin and heart, fatty liver, splenic 
abnormality
P♀2 (BDF1)
Died at 2 years 1 
month
Not determined Not available
P♀3 (BDF1) Died at 2 years Not determined Not available
P♀4 (BDF1) Killed at 2 years Killed No remarkable change
P♀5 (BDF1)
Killed at 1 year 3 
months
Killed Fatty liver, splenic abnormality
P♂1 (C57BL/6) Died at 3 months Not determined Not available
P♂2 (BDF1)
Killed at 1 year 3 
months
Killed Fatty liver
P♂3 (BDF1)
Died at 1 years 5 
months
Rupture of 
hemangioma
Hemanginoma in spleen
P♂4 (BDF1) Killed at 2 years Killed
Fatty liver, splenic abnormality, renal 
cysts
P♂5 (BDF1)
Died at 1 years 2 
months
Not determined Not available
P♂6 (BDF1) Killed at 2 year Killed No remarkable change
P♂7 (BDF1) Killed at 1 year Killed Fatty liver, splenic abnormality
P♂8 (BDF1)
Died at 1 years 10 
months
Pulmonary 
emphysema
Severe pulmonary emphysema
Table 4: Possible cause of death and histopathological features of TSC-22 transgenic F1 mice
F1 mice Died or killed Possible cause of 
death
Histopathological 
features
Reproductive 
function
3#8♀ (P♀2)
Died at 2 years 4 
months
Lung cancer
Adenocarcinoma of 
lung with mediastinal 
metastasis
Not mated
3#5♂ (P♀2) Died at 1 month Not determined Not available Not mated
4#2♀ (P♀2) Died Not determined Not available Sterile
4#4♀(P♀4)
Died at 2 year 2 
months
Malignant lymphoma
Multiple metastasis of 
malignant lymphoma
Not mated
4#1♂ (P♀4) Killed at 7 months Killed
Fibrosis of skin, 
splenic abnormality
Not mated
4#5♂ (P♀4)
Died at 2 years 2 
months
Rupture of 
hemangioma
Hemanginoma in liver Fertile
1#5♀ (P♀5)
Killed at 1 year 2 
months
Killed
Fatty liver, splenic 
abnormality
Not mated
1#6♀ (P♀5) Died Not determined Not available Sterile
(Continued )
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F1 mice Died or killed Possible cause of 
death
Histopathological 
features
Reproductive 
function
1#7♀ (P♀5)
Killed at 1 year 2 
months
Killed
Fatty liver, splenic 
abnormality
Not mated
2#4♂ (P♀5) Died Not determined Not available Fertile
2#7♀ (P♀5)
Died at 2 years 8 
months
Malignant lymphoma
Multiple metastasis of 
malignant lymphoma
Sterile
2#10♀ (P♂3)
Died at 2 years 5 
months
Rupture of 
hemangioma
Hemanginoma in 
liver, pulmonary 
emphysema, splenic 
abnormality
Sterile
3#7♀ (P♂3)
Died at 2 years 8 
months
Malignant lymphoma
Multiple metastasis 
of malignant 
lymphoma, renal cysts 
adenocarcinoma of 
lung, hemanginoma in 
liver
Sterile
3#6♂ (P♂3) Died at 2 years Not determined Not available Sterile
2#2♂ (P♂4) Killed at 7 months Killed
Fibrosis of skin, 
splenic abnormality
Not mated
4#5♀ (P♂4) Died Not determined Not available Still birth once
4#6♀ (P♂4)
Died at 1 year 2 
months
Not determined Not available Not mated
4#7♀ (P♂4) Died at 2 years Malignant lymphoma
Multiple metastasis of 
malignant lymphoma
Still birth three times
3#3♀ (P♂5)
Died at 1 year 10 
months
Not determined Not available Sterile
1#6♀ (P♂7)
Died at 2 years 4 
months
Not determined Not available Sterile
1#7♀ (P♂7)
Died at 2 years 5 
months
Malignant lymphoma
Multiple metastasis of 
malignant lymphoma
Not mated
3#4♂ (P♂7)
Died at 1 year 5 
months
Pulmonary 
emphysema
Severe pulmonary 
emphysema, sclerosis 
of heart
Not mated
3#9♂ (P♂7) Killed at 2 years Killed
Fatty liver, splenic 
abnormality
Not mated
3#10♂ (P♂7) Killed at 2 years Killed
Adenocarcinoma of 
lung
Not mated
3#11♂ (P♂7) Killed at 2 years Killed
Fatty liver, splenic 
abnormality
Not mated
4#3♀ (P♂7)
Killed at 1 year 
11months
Killed
Fatty liver, splenic 
abnormality
Sterile
4#5♀ (P♂7) Died Not determined Not available Sterile
4#6♀ (P♂7)
Died at 1 year 
11months
Malignant lymphoma
Multiple metastasis of 
malignant lymphoma
Sterile
(Continued )
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AGG AG-3’ as a down stream primer). PCR was performed 
as follows: the final concentration of dNTPs and primers in 
the reaction mixture were 200 μM and 1 μM, respectively. 
Taq DNA polymerase (Takara Biomedicals) was added to 
the mixture at a final concentration of 0.05 U/μ1, and the 
reaction was carried out in a Takara Thermal Cycler MP 
(Takara Biomedicals) under the following conditions: 94°C 
for 3 min and then 94°C for 1 min, 62°C for 1.5 min, 72°C 
for 2.5 min for 25 cycles, and extension at 72°C for 4 min.
Expression of TSC-22-GFP fusion protein in the 
transgenic founders
Total RNA was extracted from tail biopsy in the 
transgenic founders by use of ISOGEN RNA extracting 
mixture (Nippon Gene, Toyama, Japan). The RNA was 
reverse-transcribed by Moloney murine leukemia virus 
(Life Technologies, Inc.) at 42°C for 60 min using random 
primer (5 μM; Life Technologies, Inc.) in 20 μ1 of the 
reaction mixture. Subsequently, one microliter of the 
products was subjected to PCR amplification. PCR was 
performed under the same condition as described above.
Primary cultured-keratinocytes were obtained 
from the tail biopsy following a standard protocol [39]. 
Keratinocytes were seeded on the cover glass (Muto pure 
chemicals Co., Tokyo, Japan) in 35-mm culture dishes. 
Twenty-four hour after inoculation, GFP fluorescence 
in the cultured cells was observed by the fluorescent-
microscopy as described above.
Breeding of transgenic mice
All mice were housed and bred in Laboratory 
Animal Research Center, Dokkyo Medical University 
School of Medicine with controlled photoperiods (14 hours 
light and 10 hours darkness), temperature, and humidity. 
The animals were maintained and treated in accordance 
with the policies of Dokkyo Medical University’s Animal 
Care and Use Committee. Mice were sacrificed by 
exsanguination under sodium pentobarbital anesthesia. 
Founder mice of TSC-22 transgenic mice were crossed 
with wild type C57BL6/J mice or wild type BDF1 mice 
to generate F1 generation. To assess fertility, pairs of 
the transgenic mice and wild type partners were housed 
in individual cages and numbers of pups per litter were 
recorded. Genotyping of the pups was performed by PCR 
method as described above. Body weight of the transgenic 
mice was measured at least once a week. Furthermore, 
behavior of the transgenic mice was carefully observed.
Determination of the expression of TSC-22-GFP 
mRNA in the F1 transgenic mice
Total RNA was extracted from several organs 
including liver, pancreas, spleen, kidney, skin, skeletal 
muscle, brain, adipose tissue, esophagus, stomach, small 
intestine, colon, lung, and heart in the representative F1 
transgenic mice by ISOGEN RNA extracting mixture 
(Nippon Gene, Toyama, Japan). Extracted total RNA was 
subjected to RT-PCR as described above.
Histological examination
Several organs in the transgenic mice including 
liver, pancreas, spleen, kidney, adrenal gland, skin, 
skeletal muscle, brain, adipose tissue, esophagus, 
stomach, small intestine, colon, lung, salivary gland, 
spinal code, bone and heart were removed. All of 
the organs removed were fixed in a neutral aqueous 
phosphate-buffered 4% solution of formaldehyde and 
embedded in paraffin wax. The tissue was cut at 2-3 μm 
thickness and stained with hematoxylin and eosin.
Immunohistochemistry
Sections (4-μm thick) were mounted on silane-
coated glass slides, deparaffinized and rinsed. After 
antigen retrieval by microwave treatment in citric 
acid buffer (pH 6.0) for 95°C for 10 min, the sections 
F1 mice Died or killed Possible cause of 
death
Histopathological 
features
Reproductive 
function
4#8♀ (P♂7)
Died at 1 year 
11months
Malignant lymphoma
Multiple metastasis of 
malignant lymphoma
Sterile
4#10♀ (P♂7)
Died at 1 year 7 
months
Malignant lymphoma
Multiple metastasis of 
malignant lymphoma
Sterile
3#2♂ (P♂8)
Died at 2 year 
10months
Malignant lymphoma
Multiple metastasis of 
malignant lymphoma
Not mated
5#7♂ (P♂8)
Died at 1 year 5 
months
Rupture of 
hemangioma, 
malignant lymphoma
Hemanginoma in 
liver, pulmonary 
emphysema, multiple 
metastasis of 
malignant lymphoma
Fertile
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were immersed in 0.3% hydrogen peroxide to block 
endogenous peroxidase activity. Subsequently, the 
sections were reacted without or with the anti-human 
CD79α primary antibody (clone HM57: Dako, 
Carpinteria, CA) for 1 h at room temperature. The 
sections were then incubated with the biotinylated 
secondary antibody in LSAB kit (Dako) for 15 min at 
room temperature. After washing with cold phosphate-
buffered saline, streptavidin-peroxidase solution in 
LSAB kit was applied for 20 min. The sections were 
washed in cold phosphate-buffered saline, allowed to 
react with 3,3'-diaminobenzidine tetrahydrochloride 
solution and 0.03% hydrogen peroxide for 3 min 
at room temperature. The sections were finally 
counterstained with hematoxylin. When we replaced 
the primary antibody with phosphate-buffered saline, 
the clear staining in all of the cells was completely 
disappeared.
Blood analysis of the TSC-22 transgenic mice
Number of red blood cells, white blood cells, and 
platelets in the blood of the transgenic mice were counted. 
Serum glucose levels in TSC-22 transgenic mice were also 
measured. Blood analyses were performed at SRL (Tokyo, 
Japan).
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